Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Africa COVID-19 Vaccine Hesitancy (ACHES)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04912284
Recruitment Status : Completed
First Posted : June 3, 2021
Last Update Posted : June 21, 2021
Sponsor:
Collaborators:
Institut de Recherche en Sciences de la Sante, Burkina Faso
University of Bamako
Cheikh Anta Diop University, Senegal
University of Sierra Leone
Gamal Abdel Nasser University of Conakry
Information provided by (Responsible Party):
Bernhard Nocht Institute for Tropical Medicine

Brief Summary:
Vaccine hesitancy is defined by the WHO's Strategic Advisory Group of Experts on Immunization as a 'delay in acceptance or refusal of vaccination despite availability of vaccination services'. This varies in form and intensity based on when and where it occurs and what vaccine is involved. Several prophylactic vaccines against COVID-19 are currently available. As the world is beginning the roll-out the first approved vaccines, little is known about people's potential acceptance of a COVID-19 vaccine in most of the African countries. ACHES (African COVID -19Vaccine Hesitancy) is an observational study aimed at measuring COVID-19 vaccine hesitancy in five west African countries and exploring causes behind the hesitancy with the main objective of informing guidelines for the proficient roll-out of the vaccines in the region.

Condition or disease
Covid19

Show Show detailed description

Layout table for study information
Study Type : Observational
Actual Enrollment : 4977 participants
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Official Title: Africa COVID-19 Vaccine Hesitancy: a Multi-country Cross-sectional Study
Actual Study Start Date : May 5, 2021
Actual Primary Completion Date : June 6, 2021
Actual Study Completion Date : June 6, 2021


Group/Cohort
General population
Questionnaire administered to adult population
Health care workers
Questionnaire administered to adult health care workers



Primary Outcome Measures :
  1. Frequency of vaccine hesitancy [ Time Frame: 1 month ]
    To describe and compare levels of COVID-19 vaccine hesitancy among the general population and health care workers in rural and urban settings across different African countries


Secondary Outcome Measures :
  1. Factors influencing vaccine hesitancy [ Time Frame: 1 month ]
    To explore factors influencing COVID-19 vaccination hesitancy among the general population and health care workers in urban and rural Africa



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

The general population will be selected in the capital and a rural area (around the capital) from each country. Approximately 5 clusters per area will be considered. The interviews will be house hold based.

Health workers will be interviewed in facilities located in the study area and selected by the local study coordinator. Only people who have direct contact with patients will be considered for the analysis. To select study participants, staff lists including social workers from each facility will be used to randomly select people to be interviewed.

Criteria

Inclusion Criteria:

General population

  • Be at least 18 years of age, be willing and able to provide written informed consent AND

Health professionals

  • To be health professionals working in health care institutions at all levels of care for the Ministry of Health (MoH)
  • freely consent to participate in the study

Exclusion Criteria:

  • All minors (<18)
  • All individuals who do not meet the inclusion criteria listed above and those who are not willing to give written informed consent for participation in this research

In Senegal

  • All those already vaccinated or being offered a vaccination for COVID-19 and refused and/or delayed the vaccination

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04912284


Locations
Layout table for location information
Burkina Faso
Henri Gautier Ouedragogo
Ouagadougou, Burkina Faso, 7192
Guinea
Alpha Mahmoud Barry
Conakry, Guinea
Mali
Seydou Doumbia
Bamako, Mali
Senegal
Sylvain Faye
Dakar, Senegal
Sierra Leone
Abdul Mbawah
Freetown, Sierra Leone
Sponsors and Collaborators
Bernhard Nocht Institute for Tropical Medicine
Institut de Recherche en Sciences de la Sante, Burkina Faso
University of Bamako
Cheikh Anta Diop University, Senegal
University of Sierra Leone
Gamal Abdel Nasser University of Conakry
Investigators
Layout table for investigator information
Principal Investigator: Daniela Fusco, PhD Bernhard Nocht Institute for Tropical Medicine
Principal Investigator: Henri Gautier Ouedraogo, Prof University of Ouagadougu
Principal Investigator: Alpha Mahmoud Barry, Dr Santé Plus
Principal Investigator: Seydou Doumbia, Prof University of Bamako
Principal Investigator: Sylvain Faye, Prof Cheikh Anta Diop University, Senegal
Principal Investigator: Abdullah Mbawah, Dr University of Freetown
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Bernhard Nocht Institute for Tropical Medicine
ClinicalTrials.gov Identifier: NCT04912284    
Other Study ID Numbers: 2021-10550-BO-ff
First Posted: June 3, 2021    Key Record Dates
Last Update Posted: June 21, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bernhard Nocht Institute for Tropical Medicine:
Vaccine hesitancy
Vaccines
West Africa
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Respiratory Tract Infections
Infections
Pneumonia, Viral
Pneumonia
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases